구강암 세포주에 대한 CKD-602의 항암 효과
Anticancer effect of CKD-602(belotecan, camtobell.) on the oral cancer cell lines
1
조회
0
다운로드
3
인용
0
참고문헌
초록
Abstract
Purpose: CKD-602, a newly developed water-soluble campthotecin analogue, is a anticancer agent which act as a DNA topoisomerase I inhibitor. CKD-602 is known as more potent and tolerable agent. The main purposes of this study were to measure the cytotoxic effect of CKD-602 on the oral cancer cell lines and to evaluate the apoptotic aspect of dead cells. Materials and Methods: To determine the cytotoxic effect of CKD-602 on the oral cancer cell lines in comparison with various cell lines, such as lung cancer and colon cancer cell lines, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assay was performed. And apoptosis was analyzed using fluorescence-activated cell sorting(FACS) system. Results: CKD-602 decreased the viability of malignant cells in a dose dependent manner and in a time dependent manner. CKD-602 showed excellent cytotoxicity to the oral cancer cell lines. Also, apoptotic portion was increased in a dose dependent manner. Conclusion: These findings indicated that CKD-602 induced apoptotic cell death in the various cell lines including oral cancer cell lines. From the results, it was suggested that CKD-602 would be a potential therapeutic agent for the oral cancer. More successive researches on the anticancer effect of CKD-602 should be performed.
참고문헌 (16)
- "Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin", 48, pp.1722~1726 (1988)
- "Differential control of transcription-induced and overall DNA supercoiling by eukaryotic topoisomerases in vitro", 15, pp.581~589 (1996)
- "Elevation of topoisomerase I messenger RNA and catalytic activity in human tumors demonstration of tumor-type specificity and implications for cancer chemotherapy", pp.539~546
- "Clinical applications of the camptothecins", 1400, pp.107~119 (1998)
- "DNA topoisomerase expression in tumors--a novel target for chemotherapy", 31, pp.631~632 (2000)
- "Overexpression of human topoisomerase I in baby hamster kidney cells:hypersensitivity of clonal isolates to camptothecin", 52, pp.525~532 (1992)
- "Immunohistochemical detection of DNA topoisomerase I in formalin fixed paraffin wax embedded normal tissues and in ovarian carcinomas", pp.247~253 (1997)
- "DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts", 246, pp.1046~1048 (1989)
- "Antitumor activity of 7-[2-", n-isopropylami, pp.581~590
- "Safety pharmacology of CKD-602, a novel anticancer agent.", pp.272~279 (2003)
- "Cancer--a matter of life and cell death", 71, pp.709~711 (1997)
- "Mechanisms and genes of cellular suicide", 267, pp.1445~1449 (1995)
- "Apoptosis by death factor", 88, pp.355~365 (1997)
- "Apoptosis in the pathogenesis and treatment of disease", 267, pp.1456~1462 (1995)
- "Historic apoptosis", 378, pp.230~ (1995)
- "Telomeric DNA damage by topoisomerase I.A possible mechanism for cell killing by camptothecin", 279, pp.12535~12541 (2004)